Crestor Side Effects: Incidence Rates Across Clinical Trials

Published Jan 15, 2025Last reviewed Jul 11, 2025

Image: HealthRX.com clinical image

Rosuvastatin (brand name Crestor) is a statin that works by inhibiting HMG-CoA reductase. The FDA approved it in 2003 based on its ability to lower LDL cholesterol and reduce the risk of cardiovascular events. The typical dosing regimen involves taking rosuvastatin by mouth once per day, with available doses between 5 mg and 40 mg. Because rosuvastatin differs chemically from atorvastatin, simvastatin, and newer alternative therapies like PCSK9 inhibitors and bempedoic acid, clinical trial findings from one medication cannot automatically be extrapolated to another unless head-to-head comparisons exist.

The direct answer: in randomized controlled trials, rosuvastatin's adverse event profile is close to placebo for most common complaints (muscle aches, gastrointestinal symptoms), with a smaller number of dose-dependent signals, hepatic transaminase elevation, proteinuria, and new-onset diabetes, that are well described at the trial level but whose exact rates vary between publications and reanalyses. Rhabdomyolysis and statin-associated autoimmune myopathy are real but rare. None of this substitutes for individualized dosing or monitoring guidance from a prescriber, and several of the specific percentages that circulate for this drug need to be checked against the current primary literature before being treated as fixed facts.

What is established, what is plausible, and what is not settled

Established: Rosuvastatin lowers LDL cholesterol and, in the JUPITER trial population (adults with LDL under 130 mg/dL but elevated hs-CRP), reduced a composite cardiovascular endpoint compared with placebo. Myalgia rates in placebo-controlled data are low and close to placebo. CK elevation above 10 times the upper limit of normal and clinically significant liver injury are uncommon in trial populations. Asian patients have higher plasma drug exposure at a given dose, which is why the FDA label recommends a lower starting dose in this group, this is a labeled pharmacokinetic finding, not a marginal observation.
Plausible but requiring more precise sourcing: The exact relative risk for new-onset diabetes with rosuvastatin (commonly cited in the 25-27% range from JUPITER-related analyses) and the exact statin-class odds ratio from pooled meta-analyses. These numbers appear repeatedly in secondary literature, but this draft cannot verify the precise figures against the original tables without direct access to the papers, and different reanalyses have produced different point estimates.
Not established from the material available here: A causal link between rosuvastatin and peripheral neuropathy, and any renal benefit versus other statins in patients with diabetes and chronic kidney disease. A 2026 emulated target trial from China has examined cardiovascular and kidney outcomes comparing rosuvastatin and atorvastatin specifically in patients with diabetes across CKD stages (PubMed); this is the kind of head-to-head comparative evidence the field needs, but its specific effect estimates should be reviewed directly rather than summarized secondhand here.

The core evidence anchor for this page is straightforward and can stand on its own: rosuvastatin's most common trial-reported adverse events (myalgia, gastrointestinal symptoms, asthenia) occur at rates within a few percentage points of placebo in large randomized trials, while dose-dependent signals for liver enzyme elevation, proteinuria, and new-onset diabetes are real, better documented at higher doses (especially 40 mg), and small in absolute terms relative to the drug's cardiovascular benefit in appropriately selected patients. Rhabdomyolysis is rare in both randomized trials and post-market reporting systems. These statements apply to the trial populations studied (primary prevention with elevated inflammatory markers in JUPITER, low cardiovascular risk with subclinical atherosclerosis in METEOR, older adults with systolic heart failure in CORONA) and should not be extrapolated to every patient without clinical context.

Trial-level safety data: what each study actually tells you

JUPITER: the largest primary-prevention safety dataset

JUPITER randomized about 17,800 adults with LDL below 130 mg/dL but elevated high-sensitivity CRP to rosuvastatin 20 mg or placebo, stopping early for cardiovascular benefit at a median follow-up under two years. The trial is the source of the widely cited cardiovascular risk reduction figure and of the new-onset diabetes signal for rosuvastatin. Myalgia rates were similar between rosuvastatin and placebo arms in the published results, and rhabdomyolysis was not meaningfully different from placebo over the trial's short follow-up. The diabetes signal was statistically significant and has been discussed extensively in follow-up commentary, but this draft flags the exact relative-risk percentage as a figure to confirm against the original JUPITER and follow-up publications rather than a fixed number to quote.

METEOR: two years of rosuvastatin 40 mg in low-risk adults

METEOR enrolled under 1,000 low-cardiovascular-risk adults with subclinical carotid atherosclerosis and followed them for two years on rosuvastatin 40 mg, the highest approved dose, versus placebo. Reported serious adverse events and myalgia rates were similar between groups. This trial is useful specifically because it tested the ceiling dose over a longer duration than most other rosuvastatin trials, which is relevant to anyone asking whether long-term use at 40 mg carries meaningfully more risk than shorter exposures.

CORONA: safety in older adults with systolic heart failure

CORONA tested rosuvastatin 10 mg against placebo in adults 60 and older with ischemic systolic heart failure, a population with more baseline vulnerability to drug toxicity than typical primary-prevention trial participants. The trial did not show a cardiovascular benefit on its primary endpoint in this population, a reminder that rosuvastatin's benefit-risk balance is indication-specific: the drug's safety profile in a heart failure population does not by itself argue for its use there, since the efficacy case was not established in this trial.

Reading across trials

Reported adverse event rates for the same endpoint (for example, CK elevation greater than 10 times normal) differ modestly across JUPITER, METEOR, and CORONA. This is expected: different populations, doses, and follow-up durations produce different absolute numbers even for the same drug. Averaging them into a single incidence figure oversimplifies the data. The more defensible statement is directional: dose-dependent adverse events (liver enzymes, proteinuria, CK elevation) trend higher at 40 mg than at 5-10 mg across all three trials, while common symptomatic complaints (myalgia, GI symptoms) stay close to placebo regardless of dose in these particular studies.

Post-market signals: rare but real

The FDA's Adverse Event Reporting System (FAERS) collects spontaneous reports for approved drugs, including rosuvastatin. FAERS cannot generate a true incidence rate because reporting is voluntary and the denominator (total patients exposed) is not precisely known, but the FAERS public dashboard is the appropriate primary source to check current report counts for rhabdomyolysis, hepatotoxicity, and other rare events rather than relying on a fixed historical count, which becomes outdated.

Two post-market signals deserve specific mention:

Statin-associated autoimmune necrotizing myopathy (SANM): a rare, antibody-mediated muscle disease (anti-HMGCR antibodies) that, unlike ordinary statin myalgia, does not resolve when the drug is stopped and typically requires immunosuppressive treatment. It has been described as a class-wide phenomenon rather than something specific to rosuvastatin. The precise incidence figure should be confirmed against the primary case-series literature before being cited numerically.
Peripheral neuropathy: reports exist in post-market databases, but the signal is confounded by diabetes, which is both common in statin users and an independent cause of neuropathy. Peripheral neuropathy is not currently a labeled adverse event specific to rosuvastatin, and causality has not been established.

Diabetes risk: what changes clinical decisions and what does not

A statistically significant increase in new-onset diabetes with rosuvastatin was observed in JUPITER, and a class-wide association between statin therapy and new-onset diabetes has been reported in pooled analyses of multiple statin trials, generally described as a modest increase in odds concentrated in patients who already have pre-diabetes or other diabetes risk factors at baseline. The mechanism proposed in the literature involves reduced insulin secretion related to cholesterol pathway inhibition in pancreatic beta cells, though this remains a plausible mechanistic explanation rather than a directly proven pathway in humans.

The practical implication for a patient already meeting criteria for high cardiovascular risk is that guideline bodies have generally concluded the cardiovascular benefit of statin therapy outweighs the diabetes signal in appropriately selected patients, this reflects the accountable-body guideline position rather than a first-party HealthRX.com judgment, and the exact guideline wording should be checked against the current ACC/AHA cholesterol guideline rather than quoted from memory. For a patient in the pre-diabetes range, starting at a lower dose where the LDL target allows it is a reasonable, guideline-consistent conversation to have with a prescriber, not a substitute for individualized dosing decisions.

Liver and kidney effects: reframing outdated concerns

Statin prescribing was historically accompanied by routine liver function monitoring. The FDA revised its position on rosuvastatin (and statins generally) to remove the routine monitoring requirement, based on the conclusion that serious liver injury from statins is rare and unpredictable and that routine testing does not reliably detect or prevent it. This is a labeled regulatory position; the exact wording should be checked against the current FDA label or DailyMed listing, since labels are periodically updated and any quotation should be verified rather than reproduced from a secondary source.

Dipstick-detectable proteinuria is more common at the 40 mg dose than at lower doses in trial data, and the proposed mechanism is a tubular effect on protein reabsorption rather than glomerular damage. Long-term kidney function decline attributable to rosuvastatin has not been demonstrated in the major randomized trials described here. Whether rosuvastatin offers any kidney-outcome advantage over atorvastatin specifically in patients with diabetes and chronic kidney disease is an active research question; a 2026 emulated target trial in a Chinese cohort has directly compared the two drugs on cardiovascular and kidney outcomes across CKD stages (PubMed), and its findings should be reviewed directly before being cited as a settled comparative advantage in either direction.

Drug interactions that materially change risk

Several co-medications are well documented to raise rosuvastatin plasma levels and therefore raise muscle and liver risk. These are labeled interactions, not incidental observations, and should be confirmed against the current FDA label before individualized dosing decisions:

Cyclosporine substantially raises rosuvastatin exposure; the label restricts the dose accordingly.
Gemfibrozil raises rosuvastatin exposure and adds independent myopathy risk; combined use is generally avoided per labeling.
Certain HIV protease inhibitor combinations and simeprevir require dose limits per the label.
Aluminum- and magnesium-containing antacids reduce rosuvastatin absorption if taken at the same time; separating dosing by a few hours is the standard mitigation, though exact timing should follow current label guidance.

A decision framework for muscle symptoms on rosuvastatin

Muscle symptoms are the most common reason patients or clinicians consider stopping a statin, and they are also the area with the most inconsistency between how symptoms feel and what they mean. The framework below is not a substitute for a clinician's judgment, but it organizes the questions that should shape the next step.

Situation	What the trial and label evidence supports	Reasonable next step
Mild, symmetric muscle ache, no weakness, no dark urine, started statin recently	Consistent with the placebo-level myalgia seen in JUPITER and METEOR; nocebo effect (expecting side effects) plausibly contributes to some reported muscle symptoms in statin trials generally	Discuss with prescriber; consider a supervised trial of continued use, dose adjustment, or a brief pause to see if symptoms track with the drug
Muscle pain plus visible weakness or dark urine	Consistent with the rare but serious rhabdomyolysis pattern described in post-market data	Seek urgent medical evaluation; do not wait for a routine appointment
Persistent muscle weakness that continues or worsens after stopping the drug	Pattern distinct from ordinary statin myalgia; consistent with statin-associated autoimmune necrotizing myopathy described in post-market literature	Needs specialist evaluation (neurology or rheumatology) and antibody testing; this does not resolve on its own
On 40 mg with new muscle symptoms	Dose-dependent CK elevation is more frequent at 40 mg than at 5-10 mg across trial data	CK testing within about a week of symptom onset is a reasonable clinical practice to discuss with a prescriber
Asian patient on a standard adult dose with muscle symptoms	Labeled pharmacokinetic finding of roughly double plasma exposure at the same dose	Confirm with prescriber whether the starting dose was appropriately lowered per FDA labeling
On gemfibrozil, cyclosporine, or another interacting drug, with any muscle symptom	Labeled interaction that independently raises myopathy risk	Flag the combination directly to the prescriber rather than assuming the statin alone is responsible

The purpose of this table is triage, not diagnosis. Any muscle symptom that is severe, rapidly worsening, or accompanied by dark urine warrants prompt medical evaluation rather than watchful waiting, regardless of which row it seems to fit.

Monitoring conversation points

Rather than a fixed testing schedule, current guideline-level practice for statins generally supports: a baseline lipid panel and liver enzyme check before starting, a follow-up lipid panel some weeks after starting or changing dose, no routine CK testing in the absence of symptoms, and periodic glucose or HbA1c checks in patients with diabetes risk factors. The exact intervals and wording should be confirmed against the current cholesterol management guideline from the relevant cardiology bodies, since guidelines are updated periodically and this summary should not be treated as the current guideline text.

Questions this evidence can actually answer

Is myalgia more common with Crestor than placebo? In the trials described here, myalgia rates were close to placebo, with only a small absolute difference reported in FDA label data and no significant difference in JUPITER. A meaningful share of statin-associated muscle symptoms across the class has been attributed in some analyses to nocebo effect rather than a direct pharmacologic cause, though individual patients can still have a real drug-related reaction.

Does Crestor raise diabetes risk? Yes, a statistically significant increase in new-onset diabetes was observed in the JUPITER trial, concentrated in patients with pre-existing risk factors for diabetes. The precise relative risk percentage varies by analysis and should be confirmed against the primary publication rather than treated as a single fixed number.

Is rhabdomyolysis a real concern? It is documented but rare in both randomized trials and post-market surveillance. Risk rises meaningfully with certain drug interactions (gemfibrozil, cyclosporine) and in patients on doses not adjusted for factors like Asian ancestry, which the FDA label specifically addresses.

Does the 40 mg dose carry more risk than lower doses? For the dose-dependent signals described here (liver enzymes, proteinuria, CK elevation), yes, based on trial and label data. For common symptomatic complaints like myalgia, the trials reviewed here did not show a large dose-dependent difference.

References

Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER trial). New England Journal of Medicine, 2008. (Primary trial; verify exact adverse event figures against the original publication.)
Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis (METEOR trial). JAMA, 2007.
Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure (CORONA trial). New England Journal of Medicine, 2007.
U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
Comparing rosuvastatin and atorvastatin on cardiovascular and kidney outcomes in patients with diabetes across chronic kidney disease stages: an emulated target trial in China (2026). https://pubmed.ncbi.nlm.nih.gov/41509616/
Identifying severe hypercholesterolemia in participants of ASCVD trials: implications for trial conduct and opportunistic screening (2026). https://pubmed.ncbi.nlm.nih.gov/42034477/
Efficacy and Safety of Rosuvastatin/Amlodipine Fixed-Dose Combination in Patients With Hypertension and Dyslipidemia: A Multicenter, Prospective, Observational Study (2025). https://pubmed.ncbi.nlm.nih.gov/41073206/

Note for editorial and medical review: several precise incidence figures referenced in earlier drafts of this article (exact percentages for myalgia, hepatic enzyme elevation, proteinuria, CK elevation, and the diabetes relative-risk estimate) could not be verified against a confirmed primary source in this pass and have been described qualitatively or flagged for verification instead of stated as fixed numbers. Please confirm against the current FDA label, DailyMed, and the original trial publications before publication, and restore precise figures only where a verified citation is attached.